chartexchange

Puma: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 8, 2026 1:14 AM EST

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Puma (NASDAQ:PBYI) reported total revenue of $55.1 million for the quarter. For long-term investors, the business is shifting focus toward clinical drug development while managing international revenue headwinds. Three things management said stand out. Puma cleared its remaining loan balance to investment firm Athyrium during the second quarter. The payoff frees up operating cash flow and leaves the business with $108.5 million in cash, cash equivalents, and marketable securities to support research and development. Puma recorded a $2.1 million cumulative reduction to Q3 2026 royalty revenue after generic versions of NERLYNX, its prescription breast cancer drug, gained market share in China. Management lowered full-year royalty guidance to a range of $18 million to $19 million as a lower contractual royalty rate takes effect. Continue reading

Read original article